Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Total Valuation
Apellis Pharmaceuticals has a market cap or net worth of $2.52B. The enterprise value is $4.03B.
Market Cap$2.52B
Enterprise Value$4.03B
Share Statistics
Apellis Pharmaceuticals has 125,682,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding125,682,260
Owned by Insiders3.43%
Owned by Institutions0.17%
Financial Efficiency
Apellis Pharmaceuticals’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -33.35%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-33.35%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee1.01M
Profits Per Employee-280.68K
Employee Count705
Asset Turnover0.80
Inventory Turnover1.45
Valuation Ratios
The current PE Ratio of Apellis Pharmaceuticals is -19.98. Apellis Pharmaceuticals’s PEG ratio is 0.31.
PE Ratio-19.98
PS Ratio0.00
PB Ratio17.30
Price to Fair Value17.30
Price to FCF-44.79
Price to Operating Cash Flow-45.00
PEG Ratio0.31
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 709.95M and earned -197.88M in profits. Earnings per share was -1.60.
Revenue709.95M
Gross Profit592.23M
Operating Income-236.39M
Pretax Income-196.72M
Net Income-197.88M
EBITDA-236.39M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was -87.87M and capital expenditures -403.00K, giving a free cash flow of -88.27M billion.
Operating Cash Flow-87.87M
Free Cash Flow-88.27M
Free Cash Flow per Share-0.70
Dividends & Yields
Apellis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-57.69%
50-Day Moving Average22.51
200-Day Moving Average30.01
Relative Strength Index (RSI)50.35
Average Volume (3m)2.62M
Important Dates
Apellis Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Apellis Pharmaceuticals as a current ratio of 4.25, with Debt / Equity ratio of 205.56%
Current Ratio4.25
Quick Ratio3.81
Debt to Market Cap0.12
Net Debt to EBITDA-0.25
Interest Coverage Ratio-5.85
Taxes
In the past 12 months, Apellis Pharmaceuticals has paid 1.16M in taxes.
Income Tax1.16M
Effective Tax Rate>-0.01
Enterprise Valuation
Apellis Pharmaceuticals EV to EBITDA ratio is -16.97, with an EV/FCF ratio of -45.46.
EV to Sales5.65
EV to EBITDA-16.97
EV to Free Cash Flow-45.46
EV to Operating Cash Flow-45.66
Balance Sheet
Apellis Pharmaceuticals has $411.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of $58.49M billion.
Cash & Marketable Securities$411.29M
Total Debt$0.00
Net Cash$58.49M
Net Cash Per Share$0.47
Tangible Book Value Per Share$1.84
Margins
Gross margin is 84.82%, with operating margin of -33.30%, and net profit margin of -27.87%.
Gross Margin84.82%
Operating Margin-33.30%
Pretax Margin-27.71%
Net Profit Margin-27.87%
EBITDA Margin-33.30%
EBIT Margin-33.40%
Analyst Forecast
The average price target for Apellis Pharmaceuticals is $39.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$39.83
Price Target Upside98.36% Upside
Analyst ConsensusModerate Buy
Analyst Count20
Revenue Growth Forecast97.02%
EPS Growth Forecast64.32%